B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

Andrew D. Zelenetz; Leo I. Gordon; Julie E. Chang; Beth Christian; Jeremy S. Abramson; Ranjana H. Advani; Nancy L. Bartlett; L. Elizabeth Budde; Paolo F. Caimi; Sven de Vos; Bhagirathbhai Dholaria; Bita Fakhri; Luis E. Fayad; Martha J. Glenn; Thomas M. Habermann; Francisco Hernandez-Ilizaliturri; Eric Hsi; Boyu Hu; Mark S. Kaminski; Christopher R. Kelsey; Nadia Khan; Susan Krivacic; Ann S. LaCasce; Megan Lim; Mayur Narkhede; Rachel Rabinovitch; Praveen Ramakrishnan; Erin Reid; Kenneth B. Roberts; Hayder Saeed; Stephen D. Smith; Jakub Svoboda; Lode J. Swinnen; Joseph Tuscano; Julie M. Vose; Mary A. Dwyer; Hema Sundar

doi:10.6004/jnccn.2021.0054

B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo F. Caimi, Sven de Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Francisco Hernandez-Ilizaliturri, Eric Hsi, Boyu Hu, Mark S. Kaminski, Christopher R. KelseyNadia Khan, Susan Krivacic, Ann S. LaCasce, Megan Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

Original language	English (US)
Pages (from-to)	1218-1230
Number of pages	13
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	19
Issue number	11
DOIs	https://doi.org/10.6004/jnccn.2021.0054
State	Published - Nov 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2021.0054

Cite this

Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., de Vos, S., Dholaria, B., Fakhri, B., Fayad, L. E., Glenn, M. J., Habermann, T. M., Hernandez-Ilizaliturri, F., Hsi, E., Hu, B., Kaminski, M. S., ... Sundar, H. (2021). B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 19(11), 1218-1230. https://doi.org/10.6004/jnccn.2021.0054

Zelenetz, AD, Gordon, LI, Chang, JE, Christian, B, Abramson, JS, Advani, RH, Bartlett, NL, Budde, LE, Caimi, PF, de Vos, S, Dholaria, B, Fakhri, B, Fayad, LE, Glenn, MJ, Habermann, TM, Hernandez-Ilizaliturri, F, Hsi, E, Hu, B, Kaminski, MS, Kelsey, CR, Khan, N, Krivacic, S, LaCasce, AS, Lim, M, Narkhede, M, Rabinovitch, R, Ramakrishnan, P, Reid, E, Roberts, KB, Saeed, H, Smith, SD, Svoboda, J, Swinnen, LJ, Tuscano, J, Vose, JM, Dwyer, MA & Sundar, H 2021, 'B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 19, no. 11, pp. 1218-1230. https://doi.org/10.6004/jnccn.2021.0054

@article{ff72906ea95c4ae3b09e01c681653ef9,

title = "B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines",

abstract = "In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.",

author = "Zelenetz, {Andrew D.} and Gordon, {Leo I.} and Chang, {Julie E.} and Beth Christian and Abramson, {Jeremy S.} and Advani, {Ranjana H.} and Bartlett, {Nancy L.} and Budde, {L. Elizabeth} and Caimi, {Paolo F.} and {de Vos}, Sven and Bhagirathbhai Dholaria and Bita Fakhri and Fayad, {Luis E.} and Glenn, {Martha J.} and Habermann, {Thomas M.} and Francisco Hernandez-Ilizaliturri and Eric Hsi and Boyu Hu and Kaminski, {Mark S.} and Kelsey, {Christopher R.} and Nadia Khan and Susan Krivacic and LaCasce, {Ann S.} and Megan Lim and Mayur Narkhede and Rachel Rabinovitch and Praveen Ramakrishnan and Erin Reid and Roberts, {Kenneth B.} and Hayder Saeed and Smith, {Stephen D.} and Jakub Svoboda and Swinnen, {Lode J.} and Joseph Tuscano and Vose, {Julie M.} and Dwyer, {Mary A.} and Hema Sundar",

year = "2021",

month = nov,

doi = "10.6004/jnccn.2021.0054",

language = "English (US)",

volume = "19",

pages = "1218--1230",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "11",

}

TY - JOUR

T1 - B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

AU - Zelenetz, Andrew D.

AU - Gordon, Leo I.

AU - Chang, Julie E.

AU - Christian, Beth

AU - Abramson, Jeremy S.

AU - Advani, Ranjana H.

AU - Bartlett, Nancy L.

AU - Budde, L. Elizabeth

AU - Caimi, Paolo F.

AU - de Vos, Sven

AU - Dholaria, Bhagirathbhai

AU - Fakhri, Bita

AU - Fayad, Luis E.

AU - Glenn, Martha J.

AU - Habermann, Thomas M.

AU - Hernandez-Ilizaliturri, Francisco

AU - Hsi, Eric

AU - Hu, Boyu

AU - Kaminski, Mark S.

AU - Kelsey, Christopher R.

AU - Khan, Nadia

AU - Krivacic, Susan

AU - LaCasce, Ann S.

AU - Lim, Megan

AU - Narkhede, Mayur

AU - Rabinovitch, Rachel

AU - Ramakrishnan, Praveen

AU - Reid, Erin

AU - Roberts, Kenneth B.

AU - Saeed, Hayder

AU - Smith, Stephen D.

AU - Svoboda, Jakub

AU - Swinnen, Lode J.

AU - Tuscano, Joseph

AU - Vose, Julie M.

AU - Dwyer, Mary A.

AU - Sundar, Hema

PY - 2021/11

Y1 - 2021/11

N2 - In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

AB - In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

UR - http://www.scopus.com/inward/record.url?scp=85120056761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120056761&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2021.0054

DO - 10.6004/jnccn.2021.0054

M3 - Article

C2 - 34781267

AN - SCOPUS:85120056761

SN - 1540-1405

VL - 19

SP - 1218

EP - 1230

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 11

ER -

B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this